Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.

A narrative mini-review highlights a gap in understanding the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause. Sex differences exist in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms and female hormones suggest potential for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression. Traditional indigenous use of psychedelics in healing rituals is noted. Risks during gestation and breastfeeding underscore the need for caution. Comprehensive research on women is lacking; public health messaging should promote risk reduction and culturally sensitive approaches.

Study at a glance

Abstract

In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause. This narrative mini-review provides a brief summary of recently published articles in this evolving therapeutic landscape and discusses critical public health implications for addressing psychedelic use for women's reproductive health. Studies have uncovered notable sex differences in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms of action and female hormones suggest opportunities for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression (PPD). Women in indigenous communities have traditionally used psychedelics as important components of healing rituals. Yet, potential risks associated with psychedelic use during the reproductive years, specifically during gestation and breastfeeding, underscore the importance of caution and informed decision-making. While there is therapeutic potential for psychedelics in women's reproductive health issues, comprehensive research pertaining to women is lacking. While rigorous scientific inquiry into the safety, efficacy, and mechanisms of action of psychedelics in women's health is paramount, public health messaging should dispel myths and promote risk reduction strategies. Collaboration with indigenous communities and vulnerable populations can enrich understanding and ensure culturally sensitive approaches. Through enhanced research and collaboration, psychedelics can be explored to potentially address unmet needs and enhance women's well-being across diverse reproductive contexts. Existing guidance fails to focus on recommendations for women, highlighting the need for harm reduction strategies.